Adaptive Biotechnologies: Transforming Disease Diagnosis and Treatment with the Power of the Adaptive Immune System.

Adaptive Biotechnologies Announces Business Update Conference Call and Webcast Scheduled for April 2, 2024

Adaptive Biotechnologies Corporation, a biotechnology company listed on the Nasdaq under the ticker symbol ADPT, is focused on translating the genetics of the adaptive immune system into clinical products for diagnosing and treating diseases. The company recently announced that it will be hosting a business update conference call and webcast on Tuesday, April 2, 2024, after the market closes at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Adaptive Biotechnologies is dedicated to harnessing the biology of the adaptive immune system to revolutionize the diagnosis and treatment of diseases. The company believes that the adaptive immune system is a powerful tool for diagnosing and treating most diseases but has not been fully utilized due to the challenges of decoding it. Adaptive Biotechnologies’ immune medicine platform enables the decoding of the genetics of the adaptive immune system with scale, precision, and speed. The company collaborates with biopharmaceutical companies, informs drug development, and develops clinical diagnostics in two main areas: Minimal Residual Disease (MRD) and Immune Medicine. Their products and pipeline aid in diagnosing, monitoring, and treating diseases such as cancer, autoimmune disorders, and infectious diseases with the goal of developing personalized immune-driven clinical products for each patient.

For inquiries from investors, Karina Calzadilla, Vice President of Investor Relations, can be reached at investors@adaptivebiotech.com. For media inquiries, contact Erica Jones, Associate Director of Corporate Communications

Leave a Reply